Just a reminder: Emergent gets paid well, even if clinical trials fail/Fierce Pharma

Reminder–from my post 6 months ago:

 October 14: from FiercePharma:

Emergent has two contracts with J&J. The first, for setup and tech transfer, is worth $135 million in 2020 and 2021. The second, for drug-substance manufacturing, will pay out $480 million in the first two years… 

When added to the value of Emergent’s contracts with AstraZeneca and the U.S. Department of Health and Human Services, the company is assured $1.5 billion that “is largely protected from clinical trial risk, through contract protections, meaning that [Emergent] will highly likely recognize the majority of the $1.5B in revenue, irrespective of the clinical outcome of these trials,” Cantor Fitzgerald said.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
Scroll to Top